Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs

Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs

US Patent 11332537 · Granted May 17, 2022

Estimated economic value: $18,763,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Agonistic antibodies that bind human CD40 and uses thereof2025
Agonistic antibodies that bind human CD40 and uses thereof2025
Agonistic antibodies that bind human CD40 and uses thereof2025
Agonistic antibodies that bind human CD40 and uses thereof2025
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treat2024
Chimeric antigen receptors targeting TIM-12023
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs2022
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs2022
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs2022
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs2022
Antibodies that bind human CD27 and uses thereof2021
Antibodies that bind human CD27 and uses thereof2021